Ericka Wong, MD


Gaps in Care in Myasthenia Gravis and Take-Home Points

Ericka Wong, MD, comments on gaps in care in myasthenia gravis and provides take-home messages for physicians treating patients with this condition.

Nicole Fowler, PhD


Incorporating Digital Cognitive Assessments in Real-World Practice: Nicole Fowler, PhD

The director of research for internal medicine and geriatrics at Indiana University School of Medicine discussed the advantages digital assessments bring to clinics, and what role they will play in the coming years. [WATCH TIME: 3 minutes]

Gerardo “Jerry” Fernandez, MD


The Future of Digital Neuropathology and the Role of AI: John F. Crary, MD, PhD; Gerardo Fernandez, MD

The neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing spoke to the role of artificial intelligence in the diagnosis of diseases from peripheral tissue biopsies and its ability to improve neuropathology. [WATCH TIME: 8 minutes]

Charbel Moussa, MBBS, PhD


Advances in Multifaceted Drug Approaches for Dementia in Movement Disorders: Charbel Moussa, MBBS, PhD

The associate professor of neurology at Georgetown University Medical Center talked about innovative treatments for dementia in movement disorders that target multiple mechanisms to effectively modify the disease. [WATCH TIME: 7 minutes]

Asim Roy, MD


Greatest Unmet Needs in Sleep Disorder Care: Asim Roy, MD

The medical director of the Ohio State Sleep Medicine Institute provided insight on areas within sleep disorder care that need improvement, including the diagnostic process.

Fábio A Nascimento, MD


EEG Talk

EEG Talk is a series dedicated to teaching electroencephalogram (EEG) reading skills in neurology in a way that is both digestible and fun. New episodes featuring special guests in the field are posted regularly on Mondays.

Hunter Davis, PharmD


Patient Reported Outcomes and Clinical Disability Outcomes in MS demonstrate the same rates of worsening when performed in neurology clinic, patient registry, and a clinical trial

Jason Freeman, MD, MBA, and Hunter Davis, PharmD, discuss the poster “Patient Reported Outcomes and Clinical Disability Outcomes in MS demonstrate the same rates of worsening when performed in neurology clinic, patient registry, and a clinical trial” presented at AAN 2023. Sponsored By Novartis.

Joe Kardine, MS, OTR, CBIS


The Future of Innovative Neurorestoration Approaches: Joe Kardine, MS, OTR, CBIS

The clinical program manager at the Jefferson Center for Neurorestoration provided commentary on the state of neurorestoration and constant transformation of the space. [WATCH TIME: 3 minutes]

Meghan Beier, PhD, MA


Strategies for Managing Changes in Cognitive Function in Multiple Sclerosis: Meghan Beier, PhD, MA

In recognition of World MS Day, the health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine discussed types of interventions for managing cognitive changes in patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Tirisham Gyang, MD


The State of Biomarkers in Multiple Sclerosis

As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.

Ralph Sacco, MD, MS, FAAN, FAHA


Need for Research on Social Determinants of Health for Stroke Outcomes: Ralph Sacco, MD, MS, FAAN, FAHA

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed the reasons behind the lack of research on social determinants of health on stroke outcomes.

Riley Bove, MD


Future Directions and Takeaways Regarding Anti-CD20 Therapies in MS

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.

Sarah Todd Hammer


Changing the Perception and Conversation Around Disability: Sarah Todd Hammer

Hammer, a patient advocate living with acute flaccid myelitis, discussed the language around neurologic disability, and how the conversations should shift going forward. [WATCH TIME: 4 minutes]

Renã A. S. Robinson, PhD


Insights on Addressing Disparities in Alzheimer Disease Research: Renã A. S. Robinson, PhD

The full professor of chemistry at Vanderbilt University talked about research surrounding racial and ethnic disparities in Alzheimer disease incidence. [WATCH TIME: 5 minutes]

Adolfo Ramirez-Zamora, MD


Parkinson Disease Subtyping: Are We There Yet?

Heterogeneity suggests that identifying different types of Parkinson disease could improve patient management, the understanding of underlying disease mechanisms, and the development of target-specific therapies.

David G. Standaert, MD, PhD


AUPN Leadership Minute Episode 37: International Physicians in Neurology

Episode 37 of the AUPN Leadership Minute features David G. Standaert, MD, PhD, of the University of Alabama at Birmingham; and Erica A. Schuyler, MD, of the University of Connecticut. [WATCH TIME: 5 minutes]

Divyanshu Dubey, MBBS


Diagnostic Criteria, Phenotypes and Epidemiology of Autoimmune Encephalitis: Divyanshu Dubey, MBBS

The assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]

Gabrielle Macaron, MD


Clinical Pearls for MS Management in Everyday Practice

Dr Macaron shares her interpretation of the data and importance of individualizing treatment for patients with multiple sclerosis.

Joaquim Ferreira, MD, PhD


Joaquim Ferreira, MD, PhD: The Magnitude of Effect for Opicapone in Parkinson Disease

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

Lauren Elman, MD


Transition of Care in Young Adults With Spinal Muscular Atrophy

Medical professionals explore the challenges and considerations associated with patients with spinal muscular atrophy (SMA) transitioning to independent living, emphasizing the importance of maintaining continuity of care and addressing potential adherence issues to ensure optimal disease management.

Santosh Murthy, MD, MPH


A National Registry Analysis on Minimally Invasive Surgery for Intracerebral Hemorrhage: Santosh Murthy, MD, MPH

The associate professor of neurology at Weill Cornell Medicine talked about a recent study that revealed that minimally invasive surgery significantly reduced the risk of mortality in patients with nontraumatic intracerebral hemorrhage. [WATCH TIME: 4 minutes]

Joanne Taylor, PhD


Insights on GBA1-Targeting Agent GT-02287 for Parkinson Disease: Joanne Taylor, PhD

The senior vice president of research at Gain Therapeutics talked about preclinical findings from a study assessing GT-02287, an agent in development for the treatment of GBA1 Parkinson disease, and future plans for clinical trials. [WATCH TIME: 7 minutes]

Mina S. Makary, MD


Stroke Intervention: A New Application of Interventional Neuroradiology

New training pathways are needed to close the gap between capable-physician supply and the growing demand for thrombectomy.

Stephanie Richardson, MS, CCC-SLP


Swallow This: Treating Dysphagia with Speech Pathology

Stephanie Richardson, MS, CCC-SLP, an outpatient lead speech-language pathologist at Brooks Rehabilitation, discussed the unique aspects of speech therapy and the pivotal role it plays in helping patients with swallowing and other related functions.

Gina Murdoch


Advice for Physicians and the Multiple Sclerosis Community

The panel shares final advice for the multiple sclerosis community.

Yung Chyung, MD


The Outlook for Apitegromab and Its Phase 3 Trial: Yung Chyung, MD

The chief medical officer of Scholar Rock discussed the upcoming phase 3 trial for apitegromab in SMA and whether a successful trial would warrant FDA submission.

Aravindhan Veerapandiyan, MD


Early Insights on 3 Patients With DMD From Trial Assessing Gene Therapy RGX-202: Aravindhan Veerapandiyan, MD

The pediatric neuromuscular neurologist at Arkansas Children's Hospital and associate professor of pediatrics at the University of Arkansas for Medical Sciences talked about findings from a phase 1/2 study on dosing 3 pediatric patients with Duchenne muscular dystrophy with REGENXBIO’s RGX-202. [WATCH TIME: 4 minutes]

Williem de Haan, MD, PhD


Therapeutic Advantages to Using EEG to Assess Alzheimer Agents: Williem de Haan, MD, PhD

The neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]

© 2024 MJH Life Sciences

All rights reserved.